BioSpace News Archive

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628) announces encouraging phase I clinical data of TST002 (Blosozumab) in Chinese patients with reduced bone mineral density (BMD). TST002 (Blosozumab) was well tolerated and significantly increased BMD at day 85 following single intravenous injection at various doses.

BioArctic AB’s partner Eisai announced the publication of results from a simulation study evaluating the societal value of lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease, in the context of the Japanese health care system in the peer-reviewed journal Neurology and Therapy.

Takeda (TSE: 4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Takeda’s Biologics License Application (BLA) for TAK-755, an enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP), an ADAMTS13 deficiency disorder.

Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry